Inpatient Heroin Treatment Centers: Find Residential Rehab

Inpatient heroin treatment begins with medically supervised detox (5–10 days), followed by residential rehab (28–90 days) covering behavioral therapy, MAT, and relapse prevention. Because most street heroin in 2025 contains fentanyl, withdrawal timelines and overdose risks differ from historical norms — medical supervision is critical.

Heroin Treatment in 2025: What's Changed

A patient who walks into a treatment program in 2025 describing heroin use is, in most U.S. markets, describing a supply that is significantly or entirely fentanyl. This is not a fringe observation — it is DEA-reported, emergency-room-documented, and built into current addiction-medicine practice. The clinical implications are substantial, and this section is the primary reason most older heroin treatment pages are outdated.

Why most heroin today contains fentanyl and what that means for treatment

Fentanyl is roughly 50 times more potent than heroin by weight and vastly cheaper to produce and transport. For supply-side economic reasons, fentanyl began displacing heroin in U.S. illicit opioid markets in the mid-2010s and became dominant by the early 2020s. DEA laboratory reports consistently show the majority of seized heroin samples contain fentanyl or fentanyl analogs, and in some urban markets the percentage exceeds 80%. For the patient, this means the substance they were using is pharmacologically closer to fentanyl than to traditional heroin — even if they thought they were using heroin.

Three clinical implications follow. First, withdrawal onset is faster than classical heroin textbooks predict, often within 6–12 hours of last use rather than 8–24. Second, overdose risk per use is dramatically higher — fentanyl's narrow margin between therapeutic effect and respiratory depression is the primary driver of the U.S. overdose surge. Third, standard buprenorphine induction protocols designed for heroin can precipitate withdrawal in fentanyl-exposed patients because fentanyl is stored in fatty tissue and released back into circulation slowly after the last dose. All three factors make medical supervision during detox more important, not less, for patients who identify as heroin users today.

How fentanyl contamination changes the detox timeline

Inpatient heroin detox protocols have adapted. Three adjustments are now common:

• Delayed or micro-induction buprenorphine starts. Rather than a single standard induction dose once COWS ≥ 11–13, many programs use a low-dose micro-induction over 3–5 days to avoid precipitating withdrawal from residual fentanyl in circulation. Micro-induction protocols typically start at 0.5 mg twice daily and titrate upward over the first week.
• Short-course methadone bridging. Some inpatient programs use short-course methadone (permitted under the 72-hour rule in non-OTP settings for acute withdrawal management) to stabilize a fentanyl-using patient before converting to buprenorphine for continuation.
• Extended medical monitoring. Because fentanyl releases from fatty tissue over days, COWS scoring and dose adjustment frequently continues longer than the classical 5–7 day heroin timeline — often 7–10 days with more intensive monitoring at the front end.

What Inpatient Heroin Treatment Involves

Care unfolds in two overlapping phases — medical detox and residential rehabilitation — delivered under one admission. The goal is to get the patient safely through acute withdrawal and into a structured program that addresses the behavioral and environmental drivers of continued use.

Medical detox (5–10 days)

Detox begins at admission. A physician and nursing team assesses the patient, baseline labs are drawn (including toxicology that often detects fentanyl even when the patient reports heroin), and supportive medications are started: clonidine for autonomic symptoms, ondansetron for nausea, loperamide for GI distress, and non-opioid analgesics for bone and joint aches. COWS scoring is done every 2–4 hours. Buprenorphine induction begins once COWS scores are in the appropriate range — either a standard induction or a micro-induction protocol, depending on fentanyl exposure. Most patients are medically stable by day 5–7 and transition into the rehab phase around day 7–10.

Residential treatment (28–90 days)

After detox stabilization, the patient enters the structured residential phase. Daily programming includes individual therapy, group therapy, psychoeducation on addiction neurobiology and relapse triggers, trauma-informed therapy when appropriate, and recovery-skills training. Family programming is usually offered in weeks 2 or 3. Buprenorphine or naltrexone continues. Discharge planning — including outpatient MAT continuation, step-down intensive outpatient or partial hospitalization, sober living, and peer recovery support — begins on admission and is updated weekly.

MAT options for heroin addiction (buprenorphine, naltrexone)

For patients with predominantly heroin (fentanyl-contaminated heroin) use, buprenorphine is the most common inpatient medication — typically inducted during detox and continued through rehab. Extended-release depot injectable buprenorphine (Sublocade) is increasingly used as a discharge medication: a monthly injection that removes the daily adherence burden. Extended-release naltrexone (Vivitrol) is an alternative for patients who prefer an antagonist and are able to complete full detoxification before induction — typically initiated in the second or third week of inpatient stay. Our MAT page covers the medications in more depth.

Why Heroin Has One of the Highest Relapse Rates of Any Substance

Heroin and fentanyl are among the most relapse-prone substances in addiction medicine. Understanding why is essential to understanding why inpatient care is the recommended level.

Relapse rates without inpatient treatment

Multiple research groups have reported opioid relapse rates in the 40–60% range in the first year after treatment, with higher rates (often cited at 70–90%) for heroin specifically when patients attempt recovery without residential care. The relapse rate is driven by the pharmacology of opioid craving (persists months after acute withdrawal), the cue-reactivity of the home environment (locations and people associated with use remain powerful triggers), and — distinctively — the fatality risk of relapse. Because opioid tolerance falls sharply during abstinence, a dose that was sub-intoxicating during active use can be fatal after even a brief sober window. This is the clinical reason inpatient care is recommended for moderate-to-severe heroin use disorder: the relapse risk is high and the consequence of relapse is disproportionately lethal.

Why inpatient is the recommended level of care for heroin

The American Society of Addiction Medicine, NIDA, and SAMHSA all recommend residential care as the appropriate initial level of treatment for moderate-to-severe opioid use disorder. Residential care removes the patient from high-risk environments, provides medical monitoring during the highest-lethality window (the first two weeks of abstinence), and establishes MAT before discharge. Outpatient treatment has a legitimate step-down role but is not clinically equivalent as an initial intervention for most heroin patients.

What to Look for in a Heroin Treatment Center

A small set of program attributes correlates with better outcomes:

• Appropriate ASAM level. Most heroin patients need Level 3.5 (Clinically Managed High-Intensity Residential) at minimum; Level 3.7 (Medically Monitored Intensive Inpatient) for those with medical complications or severe withdrawal risk.
• Integrated MAT. Programs that initiate buprenorphine or naltrexone during the stay outperform abstinence-only programs on retention and survival.
• Fentanyl-aware detox protocols. Ask specifically about micro-induction protocols or methadone bridging — programs that have updated practice in the last several years will have clear answers.
• Licensed clinical staff. Licensed clinicians delivering evidence-based therapies (CBT, motivational interviewing, contingency management, trauma-focused therapy when indicated).
• In-network coverage. Verification of benefits should be completed before admission to cap out-of-pocket cost.
• Discharge planning. Documented transition to outpatient MAT, step-down care, and community recovery support.

How Insurance Covers Inpatient Heroin Rehab

Under MHPAEA, commercial plans must cover medically necessary inpatient heroin treatment on parity with other inpatient hospital care. Coverage typically includes detox, residential rehab, MAT, and step-down services. Patient out-of-pocket cost is bounded by the plan's deductible, coinsurance, and annual out-of-pocket maximum — most patients pay $1,000–$6,000 total for a 28-day in-network admission. Detailed coverage and appeal information is on our insurance page, and the out-of-pocket math is on the cost page.

Find Inpatient Heroin Treatment Centers Near You

Our placement specialists maintain a directory of in-network residential facilities across all 50 states with verified fentanyl-aware detox protocols and integrated MAT. The intake is short — 15 minutes for a clinical pre-screen and insurance verification — and most admissions are coordinated within 24 to 48 hours. The intake does not require the patient to be ready on day one of the call; family members and loved ones can call to understand options before the patient is ready to commit.

Frequently Asked Questions

Does heroin in 2025 really contain fentanyl?

Yes, and the data is decisive. DEA laboratory testing consistently reports the majority of seized heroin samples in the United States test positive for fentanyl or a fentanyl analog. In many urban supply chains, patients who describe themselves as heroin users are functionally using fentanyl with a heroin label. This changes treatment meaningfully: withdrawal timelines run closer to fentanyl protocols, overdose risk is higher per use, and standard buprenorphine induction needs to account for fentanyl storage in fatty tissue.

Why is heroin relapse so high?

Multiple NIDA-funded studies report relapse rates in the 40–60% range for opioid use disorder overall, with higher rates (often cited at 70–90%) for heroin specifically when patients attempt recovery without residential treatment. Three structural factors drive this: opioid craving persists long after acute withdrawal resolves, lowered tolerance after detox makes relapse episodes disproportionately fatal, and home environments typically contain the cues and access that trigger use. Inpatient residential care addresses all three directly.

How long is inpatient heroin treatment?

The standard pathway is 5–10 days of medically supervised detox followed by 28–90 days of residential rehab. NIDA research supports longer residential stays (90 days or more) for better one-year outcomes in opioid use disorder. Length of stay is a clinical decision re-evaluated by the treatment team and reauthorized by insurance every 7–14 days during the stay, not a fixed 28- or 30-day cap. Many patients continue MAT in outpatient follow-up for a year or longer after discharge.

What medications are used to treat heroin addiction?

The three FDA-approved medications are buprenorphine (often combined with naloxone as Suboxone, or as long-acting depot Sublocade), naltrexone (including extended-release Vivitrol), and methadone. Buprenorphine is the most common inpatient choice because it can be initiated during acute withdrawal, reduces craving, and can be continued in office-based practice after discharge. Naltrexone is typically initiated near the end of the inpatient stay once the patient is fully detoxified. Methadone is rarely used inpatient because federal law restricts methadone for OUD to specialized treatment programs.

What should I look for in a heroin treatment center?

Six markers matter: state licensure for inpatient residential care (ASAM Level 3.5 or 3.7), medical staffing (24-hour nursing, on-site physician or at minimum daily physician rounds), integrated MAT (not all facilities offer it), evidence-based behavioral therapy delivered by licensed clinicians, in-network status with your insurance, and a documented discharge-planning process. Ask about fentanyl-specific protocols, since many facilities have updated induction practices in the last several years.